7 289

Cited 0 times in

Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome

Authors
 Shin Hye Kim  ;  So-Hee Eun  ;  Hoon-Chul Kang  ;  Eun Ji Kwon  ;  Jung Hye Byeon  ;  Young-Mock Lee  ;  Joon Soo Lee  ;  Baik-Lin Eun  ;  Heung Dong Kim 
Citation
 SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, Vol.21(4) : 288-291, 2012 
Journal Title
 SEIZURE-EUROPEAN JOURNAL OF EPILEPSY 
ISSN
 1059-1311 
Issue Date
2012
MeSH
Adolescent ; Anticonvulsants/administration & dosage* ; Child ; Child, Preschool ; Drug Therapy, Combination ; Female ; Humans ; Infant ; Intellectual Disability/drug therapy* ; Lennox Gastaut Syndrome ; Male ; Spasms, Infantile/drug therapy* ; Triazoles/administration & dosage*
Keywords
Rufinamide ; Lennox-Gastaut syndrome ; Child
Abstract
PURPOSE: To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS). METHODS: The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included 4 weeks of scheduled titrated doses and a 12-week maintenance phase with a target dose of 20-40 mg/kg rufinamide, adjusted according to its effectiveness and tolerability after a baseline period of 4 weeks. The primary outcome was measured by the seizure-reduction rate according to individual seizure type over the 12-week maintenance period. RESULTS: One hundred and twenty-eight patients with LGS who were determined to be unresponsive to one or more antiepileptic drugs or dietary therapy were enrolled. Of the 128 patients enrolled, 112 (87.5%) completed the study. After add-on rufinamide treatment, 46 patients (35.9%) achieved a more than 50% reduction in seizure frequency and 10 (7.8%) patients became seizure-free. When we identified those who responded with an at least 50% reduction in seizure frequency, 39.4% of the responders reported reductions in convulsive seizures, 36.4% in drop attacks, 33.3% in myoclonic seizures, and 20.0% in epileptic spasms. Overall, 32.8% of patients reported adverse effects, which were mostly mild and transient in nature. The most common adverse effects were fatigue (15 patients, 11.7%) and poor appetite (9 patients, 7.0%). Twenty-one (16.4%) patients experienced an increased seizure frequency. CONCLUSIONS: Rufinamide appears to be a safe and effective adjuvant treatment for many cases of intractable LGS.
Full Text
http://www.sciencedirect.com/science/article/pii/S1059131112000453
DOI
22421185
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Hoon Chul(강훈철) ORCID logo https://orcid.org/0000-0002-3659-8847
Kwon, Eun Ji(권은지)
Kim, Shin Hye(김신혜)
Kim, Heung Dong(김흥동) ORCID logo https://orcid.org/0000-0002-8031-7336
Eun, Ho Seon(은호선) ORCID logo https://orcid.org/0000-0001-7212-0341
Lee, Young Mock(이영목) ORCID logo https://orcid.org/0000-0002-5838-249X
Lee, Joon Soo(이준수) ORCID logo https://orcid.org/0000-0001-9036-9343
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/91843
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse